Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
REGULATORY
MOF Panel Urges Govt to Use Economic Evaluations for Reimbursement Decisions: FY2019 Budget Recommendation
The Fiscal System Council submitted its recommendation paper for FY2019 budget formulations to Finance Minister Taro Aso on November 20, calling on the government to use economic evaluations when it makes go/no-go decisions on the reimbursement of drugs and other…
To read the full story
Related Article
- CEFP Finalizes Govt Reform Timeline Urging FY2019 Debate on “Economic Evaluations” for Reimbursement Decisions
December 21, 2018
- Govt’s Draft Reform Timeline Prods MHLW to Discuss Use of “Economic Evaluations” in Reimbursement Decisions in FY2019
December 11, 2018
- MOF Reiterates Drug Cost Optimization, but Makes No Fresh Proposal: Fiscal System Council
October 10, 2018
REGULATORY
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
- Japan Drug Production Up 1.5% to 6.7 Trillion Yen in 2017: MHLW Survey
April 18, 2019
- LDP Junior Lawmakers to Launch Vaccine Study Group
April 17, 2019
- Entyvio’s Crohn’s Disease Use on Agenda for April 26 MHLW Panel Meeting
April 15, 2019
- CEFP Kicks Off Discussions towards 2020 Reimbursement Policy Reform
April 11, 2019
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…
Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…